JP2017141261A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017141261A5 JP2017141261A5 JP2017056477A JP2017056477A JP2017141261A5 JP 2017141261 A5 JP2017141261 A5 JP 2017141261A5 JP 2017056477 A JP2017056477 A JP 2017056477A JP 2017056477 A JP2017056477 A JP 2017056477A JP 2017141261 A5 JP2017141261 A5 JP 2017141261A5
- Authority
- JP
- Japan
- Prior art keywords
- toxin
- bacterial
- bacterial minicell
- cancer
- minicell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000001580 bacterial Effects 0.000 claims 18
- 231100000765 Toxin Toxicity 0.000 claims 8
- 239000003053 toxin Substances 0.000 claims 8
- 201000011510 cancer Diseases 0.000 claims 7
- 210000003527 eukaryotic cell Anatomy 0.000 claims 5
- 239000003112 inhibitor Substances 0.000 claims 4
- 230000002401 inhibitory effect Effects 0.000 claims 4
- 230000001225 therapeutic Effects 0.000 claims 4
- 101700023105 3L21 Proteins 0.000 claims 3
- 108010049048 Cholera Toxin Proteins 0.000 claims 3
- 102000009016 Cholera Toxin Human genes 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 230000000975 bioactive Effects 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 150000003384 small molecules Chemical class 0.000 claims 3
- 101700012833 3S11 Proteins 0.000 claims 2
- 241000193738 Bacillus anthracis Species 0.000 claims 2
- 210000000481 Breast Anatomy 0.000 claims 2
- 210000001072 Colon Anatomy 0.000 claims 2
- 108010053187 Diphtheria Toxin Proteins 0.000 claims 2
- 102000016607 Diphtheria Toxin Human genes 0.000 claims 2
- 241000588724 Escherichia coli Species 0.000 claims 2
- 210000003238 Esophagus Anatomy 0.000 claims 2
- 210000000232 Gallbladder Anatomy 0.000 claims 2
- 102000012355 Integrin beta1 Human genes 0.000 claims 2
- 108010022222 Integrin beta1 Proteins 0.000 claims 2
- 210000000936 Intestines Anatomy 0.000 claims 2
- 210000004185 Liver Anatomy 0.000 claims 2
- 210000004072 Lung Anatomy 0.000 claims 2
- 241000193386 Lysinibacillus sphaericus Species 0.000 claims 2
- 210000000214 Mouth Anatomy 0.000 claims 2
- 210000001672 Ovary Anatomy 0.000 claims 2
- 210000000496 Pancreas Anatomy 0.000 claims 2
- 210000003899 Penis Anatomy 0.000 claims 2
- 210000003800 Pharynx Anatomy 0.000 claims 2
- 210000002307 Prostate Anatomy 0.000 claims 2
- 231100000654 Protein toxin Toxicity 0.000 claims 2
- 210000000664 Rectum Anatomy 0.000 claims 2
- 210000003491 Skin Anatomy 0.000 claims 2
- 210000002784 Stomach Anatomy 0.000 claims 2
- 210000001550 Testis Anatomy 0.000 claims 2
- 210000002105 Tongue Anatomy 0.000 claims 2
- 210000003932 Urinary Bladder Anatomy 0.000 claims 2
- 210000004291 Uterus Anatomy 0.000 claims 2
- 101710004068 VCINV Proteins 0.000 claims 2
- 210000001215 Vagina Anatomy 0.000 claims 2
- 101710037563 alpha-delta-Bgt-2 Proteins 0.000 claims 2
- 210000000436 anus Anatomy 0.000 claims 2
- 210000004027 cells Anatomy 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- -1 radioisotope Chemical class 0.000 claims 2
- 101700080113 toxB Proteins 0.000 claims 2
- 229940116904 ANTIINFLAMMATORY THERAPEUTIC RADIOPHARMACEUTICALS Drugs 0.000 claims 1
- 229940100197 ANTIMETABOLITES Drugs 0.000 claims 1
- 108010083528 Adenylate Cyclase Toxin Proteins 0.000 claims 1
- 229940046836 Anti-estrogens Drugs 0.000 claims 1
- 206010059512 Apoptosis Diseases 0.000 claims 1
- 108010093201 Arcanobacterium pyogenes Pyolysin Proteins 0.000 claims 1
- 108010043024 Botulinum Toxins Proteins 0.000 claims 1
- 241000193468 Clostridium perfringens Species 0.000 claims 1
- 229940038704 Clostridium perfringens Drugs 0.000 claims 1
- 108010065693 Clostridium perfringens theta-toxin Proteins 0.000 claims 1
- 108010089239 Gelonium multiflorum GEL protein Proteins 0.000 claims 1
- 102000009465 Growth Factor Receptors Human genes 0.000 claims 1
- 108010009202 Growth Factor Receptors Proteins 0.000 claims 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 claims 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 claims 1
- 240000005979 Hordeum vulgare Species 0.000 claims 1
- 235000007340 Hordeum vulgare Nutrition 0.000 claims 1
- 108010072255 Integrin alpha3beta1 Proteins 0.000 claims 1
- 108010008212 Integrin alpha4beta1 Proteins 0.000 claims 1
- 102000008607 Integrin beta3 Human genes 0.000 claims 1
- 108010020950 Integrin beta3 Proteins 0.000 claims 1
- 210000003734 Kidney Anatomy 0.000 claims 1
- 241000186781 Listeria Species 0.000 claims 1
- 108010027097 Listeria monocytogenes hlyA protein Proteins 0.000 claims 1
- 108010036176 Melitten Proteins 0.000 claims 1
- 206010061289 Metastatic neoplasm Diseases 0.000 claims 1
- 102000028664 Microtubules Human genes 0.000 claims 1
- 108091022031 Microtubules Proteins 0.000 claims 1
- 210000004688 Microtubules Anatomy 0.000 claims 1
- 241000186359 Mycobacterium Species 0.000 claims 1
- 229940074726 OPHTHALMOLOGIC ANTIINFLAMMATORY AGENTS Drugs 0.000 claims 1
- 108010081690 Pertussis Toxin Proteins 0.000 claims 1
- 108010077397 Pseudomonas aeruginosa toxA protein Proteins 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 108010039491 Ricin Proteins 0.000 claims 1
- 241000607142 Salmonella Species 0.000 claims 1
- 108010079723 Shiga Toxin Proteins 0.000 claims 1
- 241000607768 Shigella Species 0.000 claims 1
- 108010007006 Streptococcus pneumoniae plY protein Proteins 0.000 claims 1
- 101700057439 TOXA Proteins 0.000 claims 1
- 108010055044 Tetanus Toxin Proteins 0.000 claims 1
- 102000004243 Tubulin Human genes 0.000 claims 1
- 108090000704 Tubulin Proteins 0.000 claims 1
- 241000607734 Yersinia <bacteria> Species 0.000 claims 1
- 241000607477 Yersinia pseudotuberculosis Species 0.000 claims 1
- 101710024925 alv Proteins 0.000 claims 1
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 1
- 230000001833 anti-estrogenic Effects 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 230000000340 anti-metabolite Effects 0.000 claims 1
- 230000002927 anti-mitotic Effects 0.000 claims 1
- 239000002256 antimetabolite Substances 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- 229940053031 botulinum toxin Drugs 0.000 claims 1
- 231100001102 clostridial toxin Toxicity 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 101700041767 ctxA Proteins 0.000 claims 1
- 229920003013 deoxyribonucleic acid Polymers 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002124 endocrine Effects 0.000 claims 1
- 239000002158 endotoxin Substances 0.000 claims 1
- 239000000328 estrogen antagonist Substances 0.000 claims 1
- 239000003276 histone deacetylase inhibitor Substances 0.000 claims 1
- 229940121372 histone deacetylase inhibitors Drugs 0.000 claims 1
- 239000000411 inducer Substances 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 230000000749 insecticidal Effects 0.000 claims 1
- 108010044426 integrins Proteins 0.000 claims 1
- 102000006495 integrins Human genes 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- VDXZNPDIRNWWCW-JFTDCZMZSA-N melittin Chemical compound NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(N)=O)CC1=CNC2=CC=CC=C12 VDXZNPDIRNWWCW-JFTDCZMZSA-N 0.000 claims 1
- 230000001394 metastastic Effects 0.000 claims 1
- 230000000051 modifying Effects 0.000 claims 1
- 239000003865 nucleic acid synthesis inhibitor Substances 0.000 claims 1
- 230000004792 oxidative damage Effects 0.000 claims 1
- 230000022983 regulation of cell cycle Effects 0.000 claims 1
- 150000004492 retinoid derivatives Chemical class 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 claims 1
- 108010075210 streptolysin O Proteins 0.000 claims 1
- 229940118376 tetanus toxin Drugs 0.000 claims 1
- 230000035897 transcription Effects 0.000 claims 1
Claims (19)
- ストレプトリシンＯ、ペルフリンゴリシンＯ、またはリステリオリシンＯを含む、細菌ミニ細胞。
- さらにインベイシン（Ｉｎｖａｓｉｎ）を含む、請求項１に記載の細菌ミニ細胞。
- 前記インベイシン（Ｉｎｖａｓｉｎ）が、エルシニア・シュードツベルクロシス（Ｙｅｒｓｉｎｉａ ｐｓｅｕｄｏｔｕｂｅｒｃｕｌｏｓｉｓ）由来である、請求項２に記載の細菌ミニ細胞。
- さらにタンパク毒素を含む、請求項１〜３のいずれか１項に記載の細菌ミニ細胞。
- 前記タンパク毒素が、ゲロニン、ジフテリア毒素Ａ断片、ジフテリア毒素Ａ／Ｂ断片、破傷風毒素、大腸菌熱不安定性毒素、コレラ毒素、ウエルシュ菌のイオタ毒素、シュードモナス外毒素Ａ、志賀毒素、炭疽菌毒素、ＭＴＸ（バチルス・スフェリカス（Ｂ．ｓｐｈａｅｒｉｃｕｓ）の殺虫毒素）、ストレプトリシン、オオムギ毒素、メリチン、炭疽菌毒素ＬＦおよびＥＦ、アデニル酸シクラーゼ毒素、ボツリノリシンＢ、ボツリノリシンＥ３、ボツリノリシンＣ、ボツリヌス毒素Ａ、コレラ毒素、クロストリジウム毒素Ａ、Ｂおよびα、リシン、志賀Ａ毒素、志賀様Ａ毒素、コレラＡ毒素、百日咳ＳＩ毒素、ストレプトリシンＯ ｃ、ストレプトリシンＯ ｅ、スフェリコリシン（ｓｐｈａｅｒｉｃｏｌｙｓｉｎ）、アントロリシン（ａｎｔｈｒｏｌｙｓｉｎ）Ｏ、セレオリシン（ｃｅｒｅｏｌｙｓｉｎ）、チューリンゲンシリシン（ｔｈｕｒｉｎｇｉｅｎｓｉｌｙｓｉｎ）Ｏ、ワイヘンステファネンシリシン（ｗｅｉｈｅｎｓｔｅｐｈａｎｅｎｓｉｌｙｓｉｎ）、アルベオリシン（ａｌｖｅｏｌｙｓｉｎ）、ブレビリシン（ｂｒｅｖｉｌｙｓｉｎ）、ブチリクリシン（ｂｕｔｙｒｉｃｕｌｙｓｉｎ）、テタノリジンＯ、ノビリシン（ｎｏｖｙｉｌｙｓｉｎ）、レクチノリシン（ｌｅｃｔｉｎｏｌｙｓｉｎ）、ニューモリシン、ミチリシン（ｍｉｔｉｌｙｓｉｎ）、シュードニューモリシン、スイリシン（ｓｕｉｌｙｓｉｎ）、インターメジリシン（ｉｎｔｅｒｍｅｄｉｌｙｓｉｎ）、イバノリシン（ｉｖａｎｏｌｙｓｉｎ）、ゼーリゲリオリシン（ｓｅｅｌｉｇｅｒｉｏｌｙｓｉｎ）Ｏ、バジノリシン（ｖａｇｉｎｏｌｙｓｉｎ）、ピオリシン（ｐｙｏｌｙｓｉｎ）、ならびにそれらの任意の組合せからなる群より選択される、請求項４に記載の細菌ミニ細胞。
- 前記細菌ミニ細胞が、サルモネラ属の種、リステリア属の種、マイコバクテリウム属の種、シゲラ属の種、エルシニア属の種または大腸菌のミニ細胞産生株から産生されたものである、請求項１〜５のいずれか１項に記載の細菌ミニ細胞。
- さらに１つ以上の生理活性分子を含む、請求項１〜６のいずれか１項に記載の細菌ミニ細胞。
- 前記１つ以上の生理活性分子が、小分子、核酸、ポリペプチド、放射性同位体、脂質、リポ多糖、またはそれらの任意の組合せを含む、請求項７に記載の細菌ミニ細胞。
- 前記１つ以上の生理活性分子のうちの少なくとも１つが、小分子治療薬、治療用核酸または治療用ポリペプチドである、請求項７に記載の細菌ミニ細胞。
- 前記小分子治療薬が、ＤＮＡ損傷剤、ＤＮＡ合成阻害剤、微小管およびチューブリン結合剤、抗代謝剤、酸化損傷誘導剤、抗血管新生剤、内分泌治療剤、抗エストロゲン剤、免疫調節因子、ヒストン脱アセチル化酵素阻害剤、シグナル伝達系の阻害剤、ヒートショックタンパク質の阻害剤、レチノイド、成長因子受容体の阻害剤、抗有糸分裂化合物、抗炎症剤、細胞周期調節因子、転写因子阻害剤、アポトーシス誘導剤、およびそれらの任意の組合せからなる群より選択される、請求項９に記載の細菌ミニ細胞。
- 請求項１〜１０のいずれか１項に記載の細菌ミニ細胞および薬学的に許容可能な担体を含む組成物。
- 請求項１〜１０のいずれか１項に記載の細菌ミニ細胞を真核細胞に接触させることを含む、細菌細胞の真核細胞への標的化方法。
- さらに、前記１つ以上の生理活性分子を前記細菌ミニ細胞から前記真核細胞に輸送することを含む、請求項１２に記載の方法。
- 前記真核細胞が癌細胞である、請求項１２または１３に記載の方法。
- 前記癌が、固形腫瘍、転移性腫瘍または液性腫瘍である、請求項１４に記載の方法。
- 前記癌が、乳腺、肺、膵臓、前立腺、精巣、卵巣、胃部、腸部、口腔、舌、咽頭、肝臓、肛門、直腸、結腸、食道、膀胱、胆嚢、皮膚、子宮、膣、陰茎または腎臓の癌である、請求項１４に記載の方法。
- 前記真核細胞が、α３β１インテグリン、α４β１インテグリン、α５β１インテグリン、α ｖ β３インテグリン、α ｖ β１インテグリン、β１インテグリンまたはこれらの組み合わせを含む、請求項１２〜１６のいずれか１項に記載の方法。
- 請求項１〜１０のいずれか１項に記載の細菌ミニ細胞を含む、癌の治療剤。
- 前記癌が、乳腺、肺、膵臓、前立腺、精巣、卵巣、胃部、腸部、口腔、舌、咽頭、肝臓、肛門、直腸、結腸、食道、膀胱、胆嚢、皮膚、子宮、膣、陰茎または腎臓の癌である、請求項１８に記載の治療剤。
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161442999P | 2011-02-15 | 2011-02-15 | |
| US61/442,999 | 2011-02-15 | ||
| US201161526219P | 2011-08-22 | 2011-08-22 | |
| US61/526,219 | 2011-08-22 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013554578A Division JP6199746B2 (ja) | 2011-02-15 | 2012-02-15 | 抗体およびＦｃ含有標的化分子に基づく生理活性分子の標的送達のための細菌ミニ細胞による治療用組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017141261A JP2017141261A (ja) | 2017-08-17 |
| JP2017141261A5 true JP2017141261A5 (ja) | 2017-11-09 |
| JP6697689B2 JP6697689B2 (ja) | 2020-05-27 |
Family
ID=46637042
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013554578A Active JP6199746B2 (ja) | 2011-02-15 | 2012-02-15 | 抗体およびＦｃ含有標的化分子に基づく生理活性分子の標的送達のための細菌ミニ細胞による治療用組成物および方法 |
| JP2017056477A Active JP6697689B2 (ja) | 2011-02-15 | 2017-03-22 | 抗体およびＦｃ含有標的化分子に基づく生理活性分子の標的送達のための細菌ミニ細胞による治療用組成物および方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013554578A Active JP6199746B2 (ja) | 2011-02-15 | 2012-02-15 | 抗体およびＦｃ含有標的化分子に基づく生理活性分子の標的送達のための細菌ミニ細胞による治療用組成物および方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US10005820B2 (ja) |
| EP (2) | EP3527222B1 (ja) |
| JP (2) | JP6199746B2 (ja) |
| AU (3) | AU2012217728B2 (ja) |
| CA (1) | CA2827443C (ja) |
| DK (1) | DK2675474T3 (ja) |
| ES (1) | ES2720659T3 (ja) |
| WO (1) | WO2012112696A1 (ja) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2675474T3 (en) * | 2011-02-15 | 2019-04-23 | Vaxiion Therapeutics Llc | THERAPEUTIC COMPOSITIONS AND PROCEDURES FOR TARGETED ADMINISTRATION OF BIOACTIVE MOLECULES BY BACK-TERIAL MINICLES BASED ON ANTIBODY AND FC-CONTAINING TAR-GETING MOLECULES |
| RS61161B1 (sr) | 2011-12-13 | 2021-01-29 | Engeneic Molecular Delivery Pty Ltd | Intaktne minićelije poreklom iz bakterija za isporuku terapijskih agenasa tumorima mozga |
| EP2833897A1 (en) * | 2012-04-05 | 2015-02-11 | Ludwig-Maximilians-Universität München | Method for the preparation of a strain- adapted vaccine |
| DE102012016004B4 (de) * | 2012-08-11 | 2017-12-28 | Identec Solutions Ag | Verfahren und Vorrichtung zur Erfassung der Anwesenheit von steinbrechenden Werkzeugen an Erdbewegungsmaschinen |
| CN102816816B (zh) * | 2012-08-29 | 2014-01-29 | 西安交通大学 | 一种球形芽孢杆菌伴胞晶体蛋白制备方法及其应用 |
| CN104837506A (zh) | 2012-10-02 | 2015-08-12 | 瓦克星治疗有限责任公司 | 免疫调节性小细胞及使用方法 |
| KR102236367B1 (ko) * | 2013-07-26 | 2021-04-05 | 삼성전자주식회사 | DARPin을 포함하는 이중 특이 키메라 단백질 |
| US10143743B2 (en) * | 2013-11-18 | 2018-12-04 | Yale University | Non-replicating bacterial nanoparticle delivery system and methods of use |
| CN108348624B (zh) * | 2015-08-04 | 2021-07-27 | 瓦克星治疗有限责任公司 | 基于细菌小细胞的生物药物的电离辐射灭菌以及使用方法 |
| SG10202007520WA (en) | 2016-03-02 | 2020-09-29 | Eisai R&D Man Co Ltd | Eribulin-based antibody-drug conjugates and methods of use |
| GB2552473A (en) * | 2016-07-21 | 2018-01-31 | Evox Therapeutics Ltd | Surface decoration of extracellular vesicles |
| HRP20191966T4 (hr) | 2016-09-13 | 2022-09-16 | Allergan, Inc. | Stabilizirani neproteinski klostridijalni pripravci toksina |
| WO2018057522A1 (en) * | 2016-09-20 | 2018-03-29 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Harnessing protein-based drugs comprising an anchor domain for use on the ocular surface |
| CN111196844B (zh) * | 2016-09-21 | 2021-11-30 | 中国农业科学院植物保护研究所 | 一种杀虫蛋白及其核酸、制备方法和应用 |
| US11485976B2 (en) * | 2016-10-06 | 2022-11-01 | Engeneic Molecular Delivery Pty Ltd | Bacterial minicells for delivering nucleic acid adjuvants and methods of using the same |
| US11167008B2 (en) | 2016-11-23 | 2021-11-09 | Vaxiion Therapeutics, Llc | Immunomodulatory and oncolytic minicells and methods of use |
| BR112019022539A2 (pt) | 2017-04-28 | 2020-06-16 | Agrospheres, Inc. | Composições e métodos para o encapsulamento e entrega escalonável de agorquímicos |
| US11624061B2 (en) | 2017-04-28 | 2023-04-11 | Agrospheres, Inc. | Compositions and methods for enzyme immobilization |
| US10470659B2 (en) * | 2017-06-08 | 2019-11-12 | Fdna Inc. | Systems, methods, and computer-readable media for gene and genetic variant prioritization |
| AU2018301716B2 (en) | 2017-07-14 | 2024-06-13 | The Regents Of The University Of California | Novel methods of predicting transplant rejection risk |
| BR112020005803A2 (pt) * | 2017-09-25 | 2020-12-01 | Agrospheres, Inc. | composições e métodos para produção e administração moduláveis de produtos biológicos |
| GB201717446D0 (en) * | 2017-10-24 | 2017-12-06 | Evox Therapeutics Ltd | Affinity purification of engineering extracellular vesicles |
| AU2019231307A1 (en) | 2018-03-09 | 2020-10-01 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Delivering biological drugs to tissues |
| US20210276971A1 (en) | 2018-06-20 | 2021-09-09 | The Research Foundation For The State University Of New York | Triazamacrocycle-derived chelator compositions for coordination of imaging and therapy metal ions and methods of using same |
| WO2020056417A1 (en) * | 2018-09-14 | 2020-03-19 | The Trustees Of Columbia University In The City Of New York | Precision cancer treatment using custom designed peptide-coated delivery vehicles and interchangeable modular antibodies |
| WO2020222161A1 (en) * | 2019-05-01 | 2020-11-05 | Engeneic Molecular Delivery Pty Ltd | Compositions comprising bacterially derived intact minicells for theranostic applications |
| CN110438057B (zh) * | 2019-08-21 | 2021-10-29 | 江南大学 | 一种蓝光控制的动态调控系统及其应用 |
| US20230211004A1 (en) * | 2019-11-22 | 2023-07-06 | University Of Georgia Research Foundation, Inc. | Tetanus toxoid and crm-based peptides and methods of use |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4968619A (en) | 1976-09-27 | 1990-11-06 | Research Corporation | Modified microorganisms and method of preparing and using same |
| US4190495A (en) | 1976-09-27 | 1980-02-26 | Research Corporation | Modified microorganisms and method of preparing and using same |
| US4431740A (en) | 1979-09-12 | 1984-02-14 | The Regents Of The University Of California | DNA Transfer vector and transformed microorganism containing human proinsulin and pre-proinsulin genes |
| US4311797A (en) | 1979-09-18 | 1982-01-19 | University Of Saskatchewan | Anucleated live E. coli vaccine |
| US4888170A (en) | 1981-10-22 | 1989-12-19 | Research Corporation | Vaccines obtained from antigenic gene products of recombinant genes |
| US4732852A (en) | 1981-11-20 | 1988-03-22 | Cetus Corporation | Site directed peptidase cleavage |
| IT1217303B (it) | 1984-02-01 | 1990-03-22 | Enterovax Res Pty Ltd | Ceppi batterici particolarmente utili per la produzione di vaccini per il trattamenmto di malattie intestinali e simili e metodo di ingegneria gentica per la produzione dei detti vaccini |
| DK219084D0 (da) | 1984-05-02 | 1984-05-02 | Frederik Carl Peter Lindberg | Antigen |
| US4782022A (en) | 1984-06-04 | 1988-11-01 | Lubrizol Genetics, Inc. | Nitrogen fixation regulator genes |
| US4895724A (en) | 1985-06-07 | 1990-01-23 | Pfizer Inc. | Chitosan compositions for controlled and prolonged release of macromolecules |
| US5338842A (en) | 1985-07-31 | 1994-08-16 | The Board Of Trustees Of Leland Stanford Jr. University | Yersinia INV nucleic acids |
| US5504005A (en) | 1987-03-02 | 1996-04-02 | Albert Einstein College Of Medicine Of Yeshiva University | Recombinant mycobacterial vaccine |
| US6168945B1 (en) | 1988-03-23 | 2001-01-02 | The Board Of Regents Of The University Of Oklahoma | Genes encoding operon and promoter for branched chain keto acid dehydrogenase of pseudomonas putida and methods |
| US5830710A (en) | 1988-09-08 | 1998-11-03 | University Of Florida | Cloned porphyromonas gingivalis genes and probes for the detection of periodontal disease |
| US6030805A (en) | 1989-05-04 | 2000-02-29 | Normark; Staffan | Fibronectin binding protein as well as its preparation |
| US6172189B1 (en) | 1990-08-24 | 2001-01-09 | Abbott Laboratories | Hepatitis C assay utilizing recombinant antigens |
| US5314695A (en) | 1990-11-13 | 1994-05-24 | Corvas International, Inc. | Tissue factor based prothrombin time reagent |
| US5834591A (en) | 1991-01-31 | 1998-11-10 | Washington University | Polypeptides and antibodies useful for the diagnosis and treatment of pathogenic neisseria and other microorganisms having type 4 pilin |
| US5348867A (en) * | 1991-11-15 | 1994-09-20 | George Georgiou | Expression of proteins on bacterial surface |
| CA2110295A1 (en) | 1992-03-30 | 1993-10-14 | Tatsuya Kurihara | Anti-hbs antibody genes and expression plasmids therefor |
| US6100066A (en) | 1992-04-09 | 2000-08-08 | University Of Saskatchewan | Nucleic acid molecules encoding Haemophilus somnus proteins |
| US5527695A (en) | 1993-01-29 | 1996-06-18 | Purdue Research Foundation | Controlled modification of eukaryotic genomes |
| US5843460A (en) | 1993-05-19 | 1998-12-01 | Institut Pasteur | Immunogenic compositions against helicobacter infection, polypeptides for use in the compositions, and nucleic acid sequences encoding said polypeptides |
| US5519134A (en) | 1994-01-11 | 1996-05-21 | Isis Pharmaceuticals, Inc. | Pyrrolidine-containing monomers and oligomers |
| US5525735A (en) | 1994-06-22 | 1996-06-11 | Affymax Technologies Nv | Methods for synthesizing diverse collections of pyrrolidine compounds |
| US5549974A (en) | 1994-06-23 | 1996-08-27 | Affymax Technologies Nv | Methods for the solid phase synthesis of thiazolidinones, metathiazanones, and derivatives thereof |
| US6150170A (en) | 1998-05-03 | 2000-11-21 | University Of Maryland At Baltimore | Method for introducing and expressing genes in animal cells, and live invasive bacterial vectors for use in the same |
| US5877159A (en) | 1995-05-03 | 1999-03-02 | University Of Maryland At Baltimore | Method for introducing and expressing genes in animal cells and live invasive bacterial vectors for use in the same |
| US5922583A (en) | 1995-10-17 | 1999-07-13 | Biostar Inc. | Methods for production of recombinant plasmids |
| WO1997014810A1 (en) | 1995-10-18 | 1997-04-24 | Pharmacia & Upjohn Company | Use of procaryotic hosts for expression of gene in eucaryotic cells |
| US5948889A (en) | 1996-05-21 | 1999-09-07 | Case Western Reserve University | Compositions and methods for screening antimicrobials |
| US5981182A (en) | 1997-03-13 | 1999-11-09 | Albert Einstein College Of Medicine Of Yeshiva University | Vector constructs for the selection and identification of open reading frames |
| GB9710699D0 (en) | 1997-05-24 | 1997-07-16 | Danbiosyst Uk | Gastro-retentive controlled release system |
| US6143566A (en) | 1997-06-23 | 2000-11-07 | The Rockfeller University | Methods of performing homologous recombination based modification of nucleic acids in recombination deficient cells and use of the modified nucleic acid products thereof |
| US6080849A (en) | 1997-09-10 | 2000-06-27 | Vion Pharmaceuticals, Inc. | Genetically modified tumor-targeted bacteria with reduced virulence |
| IL134936A0 (en) | 1997-09-10 | 2001-05-20 | Vion Pharmaceuticals Inc | Genetically modified tumor-targeted bacteria with reduced virulence |
| AU3644299A (en) | 1998-04-16 | 1999-11-01 | Regents Of The University Of California, The | A method for the targeting of proteins produced by (yersinia) into the cytosol of eukaryotic cells |
| AU4090299A (en) * | 1998-05-20 | 1999-12-06 | Sdg, Inc. | Liposomal delivery complex |
| EP1086223B1 (en) | 1998-06-01 | 2009-07-29 | Agensys, Inc. | Novel serpentine transmembrane antigens expressed in human cancers and uses thereof |
| US6004815A (en) | 1998-08-13 | 1999-12-21 | The Regents Of The University Of California | Bacteria expressing nonsecreted cytolysin as intracellular microbial delivery vehicles to eukaryotic cells |
| US20040170955A1 (en) | 2000-09-08 | 2004-09-02 | Wadih Arap | Human and mouse targeting peptides identified by phage display |
| ATE346168T1 (de) * | 2001-03-02 | 2006-12-15 | Univ Des Saarlandes Wissens Un | Funktionelles oberflächendisplay von polypeptiden |
| EP1372721A4 (en) | 2001-03-07 | 2008-04-02 | Childrens Medical Center | METHOD FOR SCREENING PEPTIDE DISPLAY LIBRARIES WITH A MINIMUM DISPLAY |
| US7396822B2 (en) | 2001-05-24 | 2008-07-08 | Vaxiion Therapeutics, Inc. | Immunogenic minicells and methods of use |
| US20030194798A1 (en) | 2001-05-24 | 2003-10-16 | Surber Mark W. | Minicell compositions and methods |
| US20030199089A1 (en) | 2001-06-05 | 2003-10-23 | Surber Mark W. | Membrane to membrane delivery |
| US20030166099A1 (en) | 2001-06-05 | 2003-09-04 | Sabbadini Roger A. | Minicells comprising membrane proteins |
| US20030194714A1 (en) | 2001-06-05 | 2003-10-16 | Sabbadini Roger A. | Minicell-based transformation |
| US20030211086A1 (en) | 2001-06-05 | 2003-11-13 | Neil Berkley | Minicell-based selective absorption |
| US20030203411A1 (en) | 2001-06-05 | 2003-10-30 | Sabbadini Roger A. | Methods of minicell-based delivery |
| US20030202937A1 (en) | 2001-06-05 | 2003-10-30 | Sabbadini Roger A. | Minicell-based diagnostics |
| EP1446489B1 (en) | 2001-10-15 | 2012-01-18 | EnGeneIC Molecular Delivery Pty Ltd. | Intact minicells as vectors for dna transfer and gene therapy in vitro and in vivo |
| US20030224444A1 (en) | 2002-02-25 | 2003-12-04 | Sabbadini Roger A. | Antibodies to native conformations of membrane proteins |
| US20030203481A1 (en) | 2002-02-25 | 2003-10-30 | Surber Mark W. | Conjugated minicells |
| US20030224369A1 (en) | 2002-02-25 | 2003-12-04 | Surber Mark W. | Reverse screening and target identification with minicells |
| US20030232335A1 (en) | 2002-02-25 | 2003-12-18 | Surber Mark W. | Minicell-based screening for compounds and proteins that modulate the activity of signalling proteins |
| US20030207833A1 (en) | 2002-02-25 | 2003-11-06 | Neil Berkley | Pharmaceutical compositions with minicells |
| EP2390308A1 (en) | 2002-02-25 | 2011-11-30 | Vaxiion Therapeutics Inc | Minicell compositions and methods |
| US20040005700A1 (en) | 2002-05-28 | 2004-01-08 | Surber Mark W. | Poroplasts |
| US20050016103A1 (en) * | 2003-07-22 | 2005-01-27 | Francesco Piccone | Concrete formwork |
| CA2549840C (en) | 2003-12-09 | 2012-03-20 | Engeneic Molecular Delivery Pty Ltd. | Targeted gene delivery to non-phagocytic mammalian cells via bacterially derived intact minicells |
| PL1718338T3 (pl) * | 2004-02-02 | 2015-12-31 | Engeneic Molecular Delivery Pty Ltd | Kompozycje oraz sposoby do celowanego dostarczania leku in vitro oraz in vivo do ssaczych komórek poprzez bakteriopochodne nienaruszone minikomórki |
| US8772013B2 (en) | 2004-02-02 | 2014-07-08 | Engeneic Molecular Delivery Pty Ltd | Methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells |
| WO2006055024A2 (en) * | 2004-04-05 | 2006-05-26 | Vaxiion Therapeutics, Inc. | Minicells as vaccines |
| NZ553910A (en) | 2004-08-26 | 2009-05-31 | Engeneic Molecular Delivery Pty | Delivering functional nucleic acids to mammalian cells via bacterially derived, intact minicells |
| US8187571B1 (en) | 2004-10-05 | 2012-05-29 | Gp Medical, Inc. | Pharmaceutical composition of nanoparticles |
| WO2006054129A1 (en) * | 2004-11-19 | 2006-05-26 | Institut Gustave Roussy | Improved treatment of cancer by double-stranded rna |
| US20100112670A1 (en) | 2008-06-25 | 2010-05-06 | Vaxiion Therapeutics, Inc. | Regulated genetic suicide mechanism compositions and methods |
| DK2675474T3 (en) | 2011-02-15 | 2019-04-23 | Vaxiion Therapeutics Llc | THERAPEUTIC COMPOSITIONS AND PROCEDURES FOR TARGETED ADMINISTRATION OF BIOACTIVE MOLECULES BY BACK-TERIAL MINICLES BASED ON ANTIBODY AND FC-CONTAINING TAR-GETING MOLECULES |
| CN104837506A (zh) | 2012-10-02 | 2015-08-12 | 瓦克星治疗有限责任公司 | 免疫调节性小细胞及使用方法 |
-
2012
- 2012-02-15 DK DK12747781.8T patent/DK2675474T3/en active
- 2012-02-15 EP EP19151744.0A patent/EP3527222B1/en active Active
- 2012-02-15 AU AU2012217728A patent/AU2012217728B2/en active Active
- 2012-02-15 US US13/397,313 patent/US10005820B2/en active Active
- 2012-02-15 CA CA2827443A patent/CA2827443C/en active Active
- 2012-02-15 JP JP2013554578A patent/JP6199746B2/ja active Active
- 2012-02-15 EP EP12747781.8A patent/EP2675474B1/en active Active
- 2012-02-15 WO PCT/US2012/025272 patent/WO2012112696A1/en active Application Filing
- 2012-02-15 ES ES12747781T patent/ES2720659T3/es active Active
-
2017
- 2017-03-22 JP JP2017056477A patent/JP6697689B2/ja active Active
- 2017-07-10 AU AU2017204745A patent/AU2017204745A1/en not_active Abandoned
-
2018
- 2018-06-07 US US16/002,918 patent/US10919942B2/en active Active
-
2019
- 2019-04-17 AU AU2019202702A patent/AU2019202702B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017141261A5 (ja) | ||
| Olekhnovich et al. | Role of nucleoid-associated proteins Hha and H-NS in expression of Salmonella enterica activators HilD, HilC, and RtsA required for cell invasion | |
| Stonehouse et al. | Integration host factor positively regulates virulence gene expression in Vibrio cholerae | |
| Rao et al. | Toward a live microbial microbicide for HIV: commensal bacteria secreting an HIV fusion inhibitor peptide | |
| Wang et al. | RNA-seq analysis identifies new genes regulated by the histone-like nucleoid structuring protein (H-NS) affecting Vibrio cholerae virulence, stress response and chemotaxis | |
| Trülzsch et al. | Contribution of the major secreted yops of Yersinia enterocolitica O: 8 to pathogenicity in the mouse infection model | |
| CN110325545B (zh) | 基于减毒细菌的蛋白递送 | |
| O’Loughlin et al. | Effect of Shiga toxin and Shiga-like toxins on eukaryotic cells | |
| Gowrishankar et al. | How is osmotic regulation of transcription of the Escherichia coli proU operon achieved? A review and a model | |
| Shimizu et al. | Shiga toxin 2 is specifically released from bacterial cells by two different mechanisms | |
| JP2014506893A5 (ja) | ||
| Cambronne et al. | Yersinia enterocolitica type III secretion: yscM1 and yscM2 regulate yop gene expression by a posttranscriptional mechanism that targets the 5′ untranslated region of yop mRNA | |
| Yaghoubi et al. | Bacteria as a double-action sword in cancer | |
| Brandimarte et al. | Endoscopic treatment of benign anastomotic esophageal stenosis with electrocautery | |
| Sun et al. | H-NS is a repressor of major virulence gene loci in Vibrio parahaemolyticus | |
| Jackson et al. | YscB of Yersinia pestis functions as a specific chaperone for YopN | |
| ES2880431T3 (es) | Bacterias de virulencia atenuada para el tratamiento de tumores sólidos malignos | |
| Williams McMackin et al. | H-NS family members MvaT and MvaU regulate the Pseudomonas aeruginosa type III secretion system | |
| Wing et al. | Regulation of IcsP, the outer membrane protease of the Shigella actin tail assembly protein IcsA, by virulence plasmid regulators VirF and VirB | |
| Lewis et al. | Salmonella enterica Serovar Typhimurium HtrA: regulation of expression and role of the chaperone and protease activities during infection | |
| Poulin-Laprade et al. | A λ Cro-like repressor is essential for the induction of conjugative transfer of SXT/R391 elements in response to DNA damage | |
| Schumann | Thermosensor systems in eubacteria | |
| Prosseda et al. | Histone-like proteins and the Shigella invasivity regulon | |
| Han et al. | A small regulatory RNA contributes to the preferential colonization of Escherichia coli O157: H7 in the large intestine in response to a low DNA concentration | |
| Tseytin et al. | The third transmembrane domain of EscR is critical for function of the enteropathogenic Escherichia coli type III secretion system |